
Acconeer - Robust financing mitigates the downside risks

Redeye states that Acconeer's Q4 2024 report was mixed, with a slight net sales miss, while EBITDA was above Redeye Research estimates (RRe), adjusting for the postponed order. Acconeer announced an impressively structured SEK50m capital raise that, once finalized, will secure a robust liquidity position. The issuance was rightly met with jubilation. Redeye adjusted its forecast and fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Acconeer - Robust financing mitigates the downside risks](#)